Madras High Court Restrains Med Manor, DM Pharma From Selling 'ZINCOMED' Over 'ZINCOVIT' Infringement
The Madras High Court on 13 November granted an interim injunction restraining Med Manor Organics and DM Pharma Private Limited from infringing Apex Laboratories Pvt Ltd's “ZINCOVIT” trade mark and copyright, or passing off their “ZINCOMED” product as that of Apex Laboratories, pending disposal of the suit.
Justice P.B. Balaji granted the injunction, observing:
“I am prima facie satisfied that the applicant has made out a case for the grant of urgent interim reliefs and dispensing with mandatory pre-institution mediation, as contemplated under Section 12A of the Commercial Courts Act, 2015. In view of the above, there shall be an order of interim injunction as prayed for in these original applications.”
Apex Laboratories, based in Chennai, filed the suit against Med Manor Organics, based in Hyderabad, and DM Pharma Private Limited, based in Baddi, Himachal Pradesh, alleging trade mark infringement, copyright infringement and passing off.
It submitted that it was incorporated in 1978, registered the “ZINCOVIT” trade mark in 1988 and began using it in 1990. It sought injunctions restraining the respondents from infringing its registered trade mark, reproducing its registered artistic work comprising the colour scheme, get-up and layout of its products, and passing off their products as those of Apex.
The respondents had applied to register “ZINCOMED” on a “proposed to be used” basis. Apex submitted that it discovered the alleged infringement in August 2026 and promptly filed the suit along with applications seeking urgent interim relief.
The Court found that Apex was the prior user and registrant of “ZINCOVIT”. It also observed that the respondents had prima facie copied the carton style and font of Apex's product, making the likelihood of confusion evident.
Further, the Bench held that failure to restrain the respondents would cause irreparable loss to Apex, affecting not only its monetary interests but also the goodwill and reputation it had built over decades. It was therefore prima facie satisfied that the matter warranted urgent interim relief and that pre-institution mediation could be dispensed with under Section 12A of the Commercial Courts Act, 2015.
Accordingly, the High Court granted the interim injunction pending disposal of the suit. It issued notice to the respondents and listed the case next for 8 January 2027.
For Apex Laboratories: Advocate R.Sathish Kumar